Murine efficacy and pharmacokinetic evaluation of the flaviviral NS5 capping enzyme 2-thioxothiazolidin-4-one inhibitor BG-323

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Bullard, Kristen M ^a   Gullberg, Rebekah C ^b   Soltani, Elnaz ^b   Steel, J Jordan ^b   Geiss, Brian J ^b   Keenan, Susan M ^a  

^a UNIVERSITY OF NORTHERN COLORADO   (United States)

^b Department of Ecosystem Science and Sustainability   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BG 323; CYTOCHROME P450; UNCLASSIFIED DRUG; 3-(5-(4-TERT-BUTYLBENZYLIDENE-4-OXO-2-THIOXO-1,3-THIAZOLIDIN-3-YL)PROPANOIC ACID; CAPPED RNA; ENZYME INHIBITOR; NS5 PROTEIN, FLAVIVIRUS; PROPIONIC ACID DERIVATIVE; THIAZOLIDINE DERIVATIVE; VIRAL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; NONHUMAN; VIREMIA; VIRUS CULTURE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION; WEST NILE FEVER; WEST NILE VIRUS; YELLOW FEVER VIRUS; ANIMAL; ANTAGONISTS AND INHIBITORS; CACO-2 CELL LINE; CHEMISTRY; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; EVALUATION STUDY; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOUSE; TISSUE DISTRIBUTION; VIROLOGY;

ARTHROPODA; DENGUE VIRUS; FLAVIVIRUS; MURINAE; MUS; POWASSAN VIRUS; WEST NILE VIRUS; YELLOW FEVER VIRUS GROUP;

ANIMALS; ANTIVIRAL AGENTS; CACO-2 CELLS; CERCOPITHECUS AETHIOPS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, INBRED ICR; PROPIONATES; RNA CAPS; THIAZOLIDINES; TISSUE DISTRIBUTION; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION; WEST NILE FEVER; WEST NILE VIRUS;

EID: 84937053560     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130083     Document Type: Article

References (39)

1. Organization WH (2014) Vector-borne diseases. Geneva, Switzerland: World Health Organization.
2. Guzman A, Isturiz RE (2010) Update on the global spread of dengue. Int J Antimicrob Agents 36: S40-S42. doi: 10.1016/j.ijantimicag.2010.11.012 PMID: 21129927
3. Heinz FX, Purcell MS, Gould EA, Howard CR, Houghton M, Moorman RJM, et al. (2000) Virus taxonomy. San Diego, CA: Academic.
4. Brinton MA (2002) The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annu Rev Microbiol 56: 371-402. PMID: 12142476
5. Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH (1985) Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229.
6. Lindenbach B, Thiel H, Rice C (2007) Flaviviridae: the viruses and their replication. In: KD M., editor. Fields virology. 5 ed. Philadelphia, PA: Lippincott-Raven Publishers.
7. Geiss BJ, Stahla H, Hannah AM, Gari HH, Keenan SM (2009) Focus on flaviviruses: current and future drug targets. Future Med Chem 2: 327-344. doi: 10.4155/fmc.09.27 PMID: 20165556
8. Dong H, Ren S, Li H, Shi PY (2008) Separate molecules of West Nile virus methyltransferase can independently catalyze the N7 and 2′O methylations of viral RNA cap. Virology 377: 1-6. doi: 10.1016/j.virol.2008.04.026 PMID: 18501946
9. Dong H, Ren S, Zhang B, Zhou Y, Puig-Basagoiti F, Li H, et al. (2008) West Nile virus methyltransferase catalyzes two methylations of the viral RNA cap through a substrate-repositioning mechanism. J Virol 82: 4295-4307. doi: 10.1128/JVI.02202-07 PMID: 18305027
10. Ray D, Shah A, Tilgner M, Guo Y, Zhao Y, Dong H, et al. (2006) West Nile virus 5′cap structure is formed by sequential guanine N-7 and ribose 2′O methylations by nonstructural protein 5. J Virol 80: 8362-8370. PMID: 16912287
11. Issur M, Geiss BJ, Bougie I, Picard-Jean F, Despins S, Mayette J, et al. (2009) The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. RNA 15: 2340-2350. doi: 10.1261/rna.1609709 PMID: 19850911
12. Hanley KA, Lee JJ, Blaney JEJ, Murphy BR, Whitehead SS (2002) Paired charge-to alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes. J Virol 76: 525-531. PMID: 11752143
13. Khromykh AA, Kenney MT, Westaway EG (1998) Trans-complementation of flavivirus RNA polymerase gene NS5 by using Kunjin virus replicon-expressing BHK cells. J Virol 72: 7270-7279. PMID: 9696822
14. Teramoto T, Boonyasuppayakorn S, Handley M, Choi KH, Padmanabahn R (2014) Substitution of NS5 N-terminal domain of dengue virus type 2 RNA with type 4 domain caused impaired replication and emergence of adaptive mutants with enhanced fitness. J Biol Chem: Epub ahead of print.
15. Stahla-Beek HJ, April DG, Saeedi BJ, Hannah AM, Keenan SM, Geiss BJ (2012) Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme. Virol J 86: 8730-8739. doi: 10.1128/JVI.00384-12 PMID: 22674988
16. Egloff MP, Benarroch D, Selisko B, Romette JL, Canard B (2002) An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO 21: 2757-2758. PMID: 12032088
17. Doherty AJ, Hakansson K, Ho CK, Shuman S, Wigley DB (1997) Crystallization of the RNA guanylyltransferase of Chlorella virus PBCV-1. Acta Crystallogr D Biol Crystallogr 53: 482-484. PMID: 15299921
18. Stehle T, Schulz GE (1990) Three-dimensional structure of the complex of guanylate kinase from yeast with its substrate GMP. J Mol Biol 211: 249-254. PMID: 1967656
19. Thompson TB, Thomas MG, Escalante-Semerena JC, Rayment I (1999) Three-dimensional structure of adenosylcobinamide kinase/adenosylcobinamide phosphate guanylyltransferase (CobU) complexed with GMP: evidence for a substrate-induced transferase active site. Biochemistry 38: 12995-13005. PMID: 10529169
20. Egloff MP, Decroly E, Malet H, Selisko B, Benarroch D, Ferron F, et al. (2007) Structural and functional analysis of methylation and 5′-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5. J Mol Biol 372: 723-736. PMID: 17686489
21. Geiss BJ, Thompson AA, Andrews AJ, Sons RL, Gari HH, Keenan SM, et al. (2009) Analysis of flavivirus NS5 methyltransferase cap binding. J Mol Biol 385: 1643-1654. doi: 10.1016/j.jmb.2008.11.058 PMID: 19101564
22. Benarroch D, Egloff MP, Mulard L, Guerreiro C, Romette JL, Canard B (2004) A structural basis for the inhibition of the NS5 dengue virus mRNA 2′-O-methyltransferase domain by ribavirin 5′triphosphate. J Biol Chem 279: 35638-35643. PMID: 15152003
23. Zhou Y, Ray D, Zhao Y, Dong H, Ren S, Li Z, et al. (2007) Structure and function of flavivirus NS5 methyltransferase. J Virol 81: 3891-3903. PMID: 17267492
24. Geiss BJ, Stahla-Beek HJ, Hannah AM, Gari HH, Henderson BR, Saeedi BJ, et al. (2011) A high-throughput screening assay for the identification of flavivirus NS5 capping enzyme GTP-binding inhibitors: implications for antiviral drug development. J Biomol Screen 16: 852-861. doi: 10.1177/1087057111412183 PMID: 21788392
25. Lanciotti RS, Roehrig JT, Deubel V, Smith JL, Parker M, Steele K, et al. (1999) Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286: 2333-2337. PMID: 10600742
26. Mitchell LA, Hansen RJ, Beaupre AJ, Gustafson DL, Dow SW (2013) Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity. Int Immunopharmacol 15: 357-363. doi: 10.1016/j.intimp.2012.11.016 PMID: 23246255
27. Hester JB, Gibson JD, Buchanan LV, Cimini MG, Clark MA, Emmert DE, et al. (2001) Progress toward the development of a safe and effective agent for treating reentrant cardica arrhythmias: synthesis and evaluation of ibutilide analogues with enhanced metabolic stability and dininished proarrhythmic potential. J Med Chem 44: 1099-1115. PMID: 11297456
28. Tandon M, O'Donnell MM, Porte A, Vensel D, Yang D, Palma R, et al. (2004) The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands. Bioorg Med Chem Lett 14: 1709-1712. PMID: 15026055
29. Manoury PM, Binet JL, Rousseau J, Lefevre-Borg F, Cavero IG (1987) Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chromic cardiovasculat diseases. J Med Chem 30: 1003-1011. PMID: 2884312
30. MacKenzie AR, Marchington AP, Middleton DS, Newman SD, Jones BC (2002) Structure-activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)-5-[2-[(3-substituted)-1-azetidinyl]ethyl]-2-piperidones. 1. Selective antagonists of the neurokinin-2 receptor. J Med Chem 45: 5365-5377. PMID: 12431064
31. Plobeck N, Delorme D, Wei ZY, Yang H, Zhou F, Schwarz P, et al. (2000) New diarylmethylpiperazines as potent and selective nonpeptidic delta opiod receptor agonists with increased in vitro metabolic stability. J Med Chem 43: 3878-3894. PMID: 11052793
32. Di L, Kerns EH (2008) Drug-like properties: concepts, structure design and methods from ADME to toxicity optimization. Burlington, MA: Academic Press.
33. Peglion JL, Goument B, Despaux N, Charlot V, Giraud H, Nisole C, et al. (2002) Improvement in the selectivity and metabolic stability of the serotonin 5-HT(1A) ligand, S 15535: a series of cis- and trans-2-(arylcycloalkylamine) 1-indanols. J Med Chem 45: 165-176. PMID: 11754589
34. Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR (2002) Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol 64: 1355-1374. PMID: 12392818
35. Fessey RE, Austin RP, Barton P, Davis AM, Wenlock MC (2006) The role of plasma protein binding in drug discovery. Pharmacokinetic profiling in drug research: biological, physicochemical, and computational strategies. Zurich, Switzerland: LogP2004, Lipophilicity Symposium. pp. 119-141.
36. Sweetana S, Akers MJ (1996) Solubility principles and practices for parenteral drug dosage form development. PDA Journal of Pharmaceutical Science and Technology 50: 330-342. PMID: 8973121
37. Pouton CW (2000) Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci 11 S93-S98. PMID: 11033431
38. Pouton CW (2006) Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 29: 278-287. PMID: 16815001
39. Lakkakula JR, Macedo Krause RW (2014) A vision for cyclodextrin nanoparticles in drug delivery systems and pharmaceutical applications. Nanomedicine (London) 9: 877-894. doi: 10.2217/nnm.14.41 PMID: 24981652